Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate

Marc Colombel, Stéphanie Filleur, Pierick Fournier, Carole Merle, Julien Guglielmi, Aurélie Courtin, Armelle Degeorges, Claire Marie Serre, Raymonde Bouvier, Philippe Clézardin, Florence Cabon

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

In order to understand why the angiogenesis inhibitor thrombospondin-1 (TSP1) is often, although not always, associated with prostatic tumors, we have investigated its relationship with the testosterone and the vasculature on which both normal and tumorigenic prostatic epithelia depend. In vivo, androgen withdrawal led to increased TSP1 production and decreased vascularization in the normal rat prostate which was reversed by androgen replacement. Androgen repression of TSP1 production occurred at the transcriptional level and was dependent on the presence of the first intron of the TSP1 gene. In an experimental model of prostate tumorigenesis, TSP1, when delivered by admixed stromal fibroblasts, markedly delayed LNCaP tumor growth and limited tumor vascularization. However, prolonged exposure to TSP1 resulted in the growth of tumors secreting high levels of vascular endothelial growth factor in the bloodstream of tumor-bearing animals and tumor growth was no longer sensitive to TSP1 inhibitory effects. Clinical evidence also suggested that prostate carcinomas are able to adapt to escape the antiangiogenic effects of TSP1. In human androgen-dependent localized prostate carcinomas, TSP1 expression was inversely correlated with blood vessel density. Androgen deprivation in patients with hormone-responsive tumors led to increased TSP1 expression and vascular regression. In contrast, despite a sustained expression in the tumor bed, TSP1 was no longer associated with decreased vascularization in hormone-refractory prostate tumors. Overall, these results suggest that the high in situ TSP1 exposure triggered by androgen deprivation in patients with prostate cancer could lead to early tumor resistance. Such patients could benefit from a combination of androgen deprivation and antiangiogenic therapy in order to minimize the induction of such tumor escape.

Original languageEnglish (US)
Pages (from-to)300-308
Number of pages9
JournalCancer Research
Volume65
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Thrombospondin 1
Angiogenesis Inhibitors
Androgens
Prostate
Neoplasms
Blood Vessels
Growth
Hormones
Tumor Escape
Carcinoma
Introns
Vascular Endothelial Growth Factor A
Testosterone
Prostatic Neoplasms
Carcinogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Colombel, M., Filleur, S., Fournier, P., Merle, C., Guglielmi, J., Courtin, A., ... Cabon, F. (2005). Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Research, 65(1), 300-308.

Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. / Colombel, Marc; Filleur, Stéphanie; Fournier, Pierick; Merle, Carole; Guglielmi, Julien; Courtin, Aurélie; Degeorges, Armelle; Serre, Claire Marie; Bouvier, Raymonde; Clézardin, Philippe; Cabon, Florence.

In: Cancer Research, Vol. 65, No. 1, 01.01.2005, p. 300-308.

Research output: Contribution to journalArticle

Colombel, M, Filleur, S, Fournier, P, Merle, C, Guglielmi, J, Courtin, A, Degeorges, A, Serre, CM, Bouvier, R, Clézardin, P & Cabon, F 2005, 'Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate', Cancer Research, vol. 65, no. 1, pp. 300-308.
Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Research. 2005 Jan 1;65(1):300-308.
Colombel, Marc ; Filleur, Stéphanie ; Fournier, Pierick ; Merle, Carole ; Guglielmi, Julien ; Courtin, Aurélie ; Degeorges, Armelle ; Serre, Claire Marie ; Bouvier, Raymonde ; Clézardin, Philippe ; Cabon, Florence. / Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. In: Cancer Research. 2005 ; Vol. 65, No. 1. pp. 300-308.
@article{0c536d8b234d468d931aa303bea2c291,
title = "Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate",
abstract = "In order to understand why the angiogenesis inhibitor thrombospondin-1 (TSP1) is often, although not always, associated with prostatic tumors, we have investigated its relationship with the testosterone and the vasculature on which both normal and tumorigenic prostatic epithelia depend. In vivo, androgen withdrawal led to increased TSP1 production and decreased vascularization in the normal rat prostate which was reversed by androgen replacement. Androgen repression of TSP1 production occurred at the transcriptional level and was dependent on the presence of the first intron of the TSP1 gene. In an experimental model of prostate tumorigenesis, TSP1, when delivered by admixed stromal fibroblasts, markedly delayed LNCaP tumor growth and limited tumor vascularization. However, prolonged exposure to TSP1 resulted in the growth of tumors secreting high levels of vascular endothelial growth factor in the bloodstream of tumor-bearing animals and tumor growth was no longer sensitive to TSP1 inhibitory effects. Clinical evidence also suggested that prostate carcinomas are able to adapt to escape the antiangiogenic effects of TSP1. In human androgen-dependent localized prostate carcinomas, TSP1 expression was inversely correlated with blood vessel density. Androgen deprivation in patients with hormone-responsive tumors led to increased TSP1 expression and vascular regression. In contrast, despite a sustained expression in the tumor bed, TSP1 was no longer associated with decreased vascularization in hormone-refractory prostate tumors. Overall, these results suggest that the high in situ TSP1 exposure triggered by androgen deprivation in patients with prostate cancer could lead to early tumor resistance. Such patients could benefit from a combination of androgen deprivation and antiangiogenic therapy in order to minimize the induction of such tumor escape.",
author = "Marc Colombel and St{\'e}phanie Filleur and Pierick Fournier and Carole Merle and Julien Guglielmi and Aur{\'e}lie Courtin and Armelle Degeorges and Serre, {Claire Marie} and Raymonde Bouvier and Philippe Cl{\'e}zardin and Florence Cabon",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "65",
pages = "300--308",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate

AU - Colombel, Marc

AU - Filleur, Stéphanie

AU - Fournier, Pierick

AU - Merle, Carole

AU - Guglielmi, Julien

AU - Courtin, Aurélie

AU - Degeorges, Armelle

AU - Serre, Claire Marie

AU - Bouvier, Raymonde

AU - Clézardin, Philippe

AU - Cabon, Florence

PY - 2005/1/1

Y1 - 2005/1/1

N2 - In order to understand why the angiogenesis inhibitor thrombospondin-1 (TSP1) is often, although not always, associated with prostatic tumors, we have investigated its relationship with the testosterone and the vasculature on which both normal and tumorigenic prostatic epithelia depend. In vivo, androgen withdrawal led to increased TSP1 production and decreased vascularization in the normal rat prostate which was reversed by androgen replacement. Androgen repression of TSP1 production occurred at the transcriptional level and was dependent on the presence of the first intron of the TSP1 gene. In an experimental model of prostate tumorigenesis, TSP1, when delivered by admixed stromal fibroblasts, markedly delayed LNCaP tumor growth and limited tumor vascularization. However, prolonged exposure to TSP1 resulted in the growth of tumors secreting high levels of vascular endothelial growth factor in the bloodstream of tumor-bearing animals and tumor growth was no longer sensitive to TSP1 inhibitory effects. Clinical evidence also suggested that prostate carcinomas are able to adapt to escape the antiangiogenic effects of TSP1. In human androgen-dependent localized prostate carcinomas, TSP1 expression was inversely correlated with blood vessel density. Androgen deprivation in patients with hormone-responsive tumors led to increased TSP1 expression and vascular regression. In contrast, despite a sustained expression in the tumor bed, TSP1 was no longer associated with decreased vascularization in hormone-refractory prostate tumors. Overall, these results suggest that the high in situ TSP1 exposure triggered by androgen deprivation in patients with prostate cancer could lead to early tumor resistance. Such patients could benefit from a combination of androgen deprivation and antiangiogenic therapy in order to minimize the induction of such tumor escape.

AB - In order to understand why the angiogenesis inhibitor thrombospondin-1 (TSP1) is often, although not always, associated with prostatic tumors, we have investigated its relationship with the testosterone and the vasculature on which both normal and tumorigenic prostatic epithelia depend. In vivo, androgen withdrawal led to increased TSP1 production and decreased vascularization in the normal rat prostate which was reversed by androgen replacement. Androgen repression of TSP1 production occurred at the transcriptional level and was dependent on the presence of the first intron of the TSP1 gene. In an experimental model of prostate tumorigenesis, TSP1, when delivered by admixed stromal fibroblasts, markedly delayed LNCaP tumor growth and limited tumor vascularization. However, prolonged exposure to TSP1 resulted in the growth of tumors secreting high levels of vascular endothelial growth factor in the bloodstream of tumor-bearing animals and tumor growth was no longer sensitive to TSP1 inhibitory effects. Clinical evidence also suggested that prostate carcinomas are able to adapt to escape the antiangiogenic effects of TSP1. In human androgen-dependent localized prostate carcinomas, TSP1 expression was inversely correlated with blood vessel density. Androgen deprivation in patients with hormone-responsive tumors led to increased TSP1 expression and vascular regression. In contrast, despite a sustained expression in the tumor bed, TSP1 was no longer associated with decreased vascularization in hormone-refractory prostate tumors. Overall, these results suggest that the high in situ TSP1 exposure triggered by androgen deprivation in patients with prostate cancer could lead to early tumor resistance. Such patients could benefit from a combination of androgen deprivation and antiangiogenic therapy in order to minimize the induction of such tumor escape.

UR - http://www.scopus.com/inward/record.url?scp=19944428379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428379&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 300

EP - 308

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -